Evelo Biosciences, Inc. - Special Call Transcript
Good morning, and welcome to Evelo conference call to discuss its efforts to develop EDP1815 for the treatment of COVID-19. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
At this time, I'd like to turn the call over to Jessica Cotrone of Evelo. Please proceed.
Thank you, Felicia. This morning, we issued a press release announcing our plan to evaluate EDP1815 for the treatment of COVID-19. The release, along with the slides we will be reviewing today, is available on our website at www.evelobio.com under the Investors tab.
With me today with prepared remarks are Simba Gill, Chief Executive Officer; and Duncan McHale, Chief Medical Officer. Mark Bodmer, our President of R&D and Chief Scientific Officer, is also on the line and will be available for Q&A.
Turning to Slide 2. Before we begin, I'd like to remind everyone that statements
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |